Rahel Ackermann-Gäumann

Rahel Ackermann-Gäumann

Auto-generated profile, based on publicly available information

Rahel Ackermann-Gäumann

Microbiologie, ADMED Analyses et Diagnostics Médicaux, Boucle de Cydalise 16, CH-2600 La Chaux-de-Fonds, Switzerland; Swiss National Reference Center for Tick-Transmitted Diseases, Boucle de Cydalise 16, CH-2600 La Chaux-de-Fonds, Switzerland

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 November 2023 in Viruses
Verified
Journal Article
Open access
PDF file
RZRoland Züst
Roland Züst
RARahel Ackermann-Gäumann
Rahel Ackermann-Gäumann
NLNicole Liechti
Nicole Liechti
DSDenise Siegrist
Denise Siegrist
SRSarah Ryter
Sarah Ryter
OEOlivier Engler
Olivier Engler
When infecting humans, Andes orthohantavirus (ANDV) may cause a severe disease called hantavirus cardiopulmonary syndrome (HCPS). Following non-specific symptoms, the infection may progress to a syndrome of hemorrhagic fever combined with hyper-acute cardiopulmonary failure. The case fatality rate ranges between 25–40%, depending on the outbreak. In this study, we present the follow-up of a male patient who recovered from HCPS six years ago. We demonstrate that the ANDV genome persists within the reproductive tract for at least 71 months. Genome sequence analysis early and late after infection reveals a low number of mutations (two single nucleotide variants and one deletion), suggesting limited replication activity. We can exclude the integration of the viral genome into the host genome, since the treatment of the specimen with RNAse led to a loss of signal. We demonstrate a long-lasting, strong neutralizing antibody response using pseudovirions expressing the ANDV glycoprotein. Taken together, our results show that ANDV has the potential for sexual transmission.

22 January 2024 in Frontiers in Immunology
Verified
Journal Article
Open access
RARahel Ackermann-Gäumann
Rahel Ackermann-Gäumann
PLPhung Lang
Phung Lang
KZKyra Zens
Kyra Zens
Tick-borne Encephalitis (TBE) is a severe disease of the Central Nervous System (CNS) caused by the tick-borne encephalitis virus (TBEV). The generation of protective immunity after TBEV infection or TBE vaccination relies on the integrated responses of many distinct cell types at distinct physical locations. While long-lasting memory immune responses, in particular, form the basis for the correlates of protection against many diseases, these correlates of protection have not yet been clearly defined for TBE. This review addresses the immune control of TBEV infection and responses to TBE vaccination. Potential correlates of protection and the durability of protection against disease are discussed, along with outstanding questions in the field and possible areas for future research.

12 October 2023 in Journal of Virological Methods
Verified
Journal Article
Open access
RARahel Ackermann-Gäumann
Rahel Ackermann-Gäumann
ABArthur Brêchet
Arthur Brêchet
JSJan Smetana
Jan Smetana
JSJiři Salát
Jiři Salát
RLReto Lienhard
Reto Lienhard
DRDaniel Ruzek
Daniel Ruzek
Vaccine-induced protection against tick-borne encephalitis virus (TBEV) is mediated by antibodies to the viral particle/envelope protein. The detection of non-structural protein 1 (NS1) specific antibodies has been suggested as a marker indicative of natural infections. However, recent work has shown that TBEV vaccines contain traces of NS1, and immunization of mice induced low amounts of NS1-specific antibodies. In this study, we investigated if vaccination induces TBEV NS1-specific antibodies in humans. Healthy army members (n = 898) were asked to fill in a questionnaire relating to flavivirus vaccination or infection, and blood samples were collected. In addition, samples of 71 suspected acute TBE cases were included. All samples were screened for the presence of TBEV NS1-specific IgG antibodies using an in-house developed ELISA. Antibodies were quantified as percent positivity in reference to a positive control. For qualitative evaluation, cut-off for positivity was defined based on the mean OD of the lower 95% of the vaccinated individuals + 3 SD. We found significantly higher NS1-specific IgG antibody titers (i.e., quantitative evaluation) in individuals having received 2, 3, or 4 or more vaccine doses than in non-vaccinated individuals. Similarly, the percentage of individuals with a positive test result (i.e., qualitative evaluation) was higher in individuals vaccinated against tick-borne encephalitis than in unvaccinated study participants. Although NS1-specific IgG titers remained at a relatively low level when compared to TBE patients, a clear distinction was not always possible. Establishing a clear cut-off point in detection systems is critical for NS1-specific antibodies to serve as a marker for distinguishing the immune response after vaccination and infection.

20 November 2025 in Ticks and Tick-borne Diseases
Verified
Journal Article
Open access
RARahel Ackermann-Gäumann
Rahel Ackermann-Gäumann
CNChristoph Niederhauser
Christoph Niederhauser
PGPeter Gowland
Peter Gowland
FAFrederick Angulo
Frederick Angulo
ALAlexandra Loew-Baselli
Alexandra Loew-Baselli
RLReto Lienhard
Reto Lienhard
Lyme borreliosis (LB), caused by Borrelia burgdorferi sensu lato (Bbsl), is a significant public health concern in Switzerland. Reliable data on seroprevalence and incidence are needed to better understand disease burden and inform prevention strategies. This study aimed to estimate the seroprevalence of Bbsl-specific antibodies and the incidence of symptomatic LB infections in the Swiss adult population. We analyzed Bbsl-specific IgG antibodies in 2,194 residual plasma samples from blood donors (aged 18-75 years) collected at seven Swiss Red Cross donation centers between September and December 2022. Samples were tested using the Liaison® Borrelia IgG VlsE chemiluminescence immunoassay and confirmed with the SeraSpot Anti-Borrelia-10 IgG assay according to National Reference Laboratory interpretative criteria. The overall seroprevalence was 6.1%, with higher prevalence in males (8.2%) than in females (2.9%) and regional variation ranging from 1.6% in Genève to 8.8% in Bern. Based on seroprevalence data, the estimated incidence of symptomatic Bbsl infections was 224 cases per 100,000 population per year (PPY). This estimate, although 1.3 times higher, is similar to the incidence derived from the Sentinella surveillance network. Using Sentinella data, clinically diagnosed erythema migrans was the most common manifestation (150 cases per 100,000 PPY), while disseminated forms, confirmed by clinical and laboratory criteria, occurred less frequently (1.0-8.5 cases per 100,000 PPY). Our findings provide critical insights into the burden of LB in Switzerland, highlight its public health relevance, and reinforce the importance of preventive measures. Future research should focus on longitudinal monitoring and harmonized methodologies to facilitate cross-country comparisons.

24 July 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
KZKyra Zens
Kyra Zens
RARahel Ackermann-Gäumann
Rahel Ackermann-Gäumann
JCJasmine Cantergiani
Jasmine Cantergiani
SPSee Pdf
See Pdf
Background: Tick-borne encephalitis (TBE) is a severe but vaccine-preventable viral infection of the central nervous system. Reported incidence does not fully capture TBE risk among unvaccinated individuals or the burden of TBE virus (TBEV) infections. To address this, we estimated TBE incidence among unvaccinated adults and TBEV infections compared with reported cases. Methods: We combined TBE surveillance data, vaccination coverage and vaccine effectiveness (VE) estimates, and published and newly generated serological data. The primary surveillance period was 2017-2021. Incidence among unvaccinated adults (IUV) was estimated by adjusting reported incidence for vaccination coverage and VE. Infection hazard (IH) was estimated from seroprevalence and seroreversion using a reversible catalytic model, and clinical fraction was calculated as IUV divided by IH. Findings: Between 2017 and 2021, an average of 268 TBE cases per year were reported among adults aged 18-79 years in Switzerland. After adjustment for vaccination, IUV was 6.56 per 100,000, exceeding the WHO “highly endemic” threshold. In Zurich, 9.9% (15/151) of adults without documented TBEV, JEV, or YFV vaccination were seropositive or borderline for TBEV-specific IgG. Across seven included cantons, pooled IH was 1.60% per year, corresponding to an estimated 10-year infection risk of approximately 15%; pooled clinical fraction was 0.50%, corresponding to approximately 200 infections per reported case. Interpretation: Reported TBE incidence substantially underestimates both disease risk among unvaccinated adults as well as total TBEV infection burden in Switzerland. Accounting for vaccination coverage, VE, and antibody seroreversion provides a more complete basis for interpreting TBE risk.

23 January 2024 in medRxiv
Verified
Preprint
Open access
PDF file
RARahel Ackermann-Gäumann
Rahel Ackermann-Gäumann
ADAlexis Dentand
Alexis Dentand
RLReto Lienhard
Reto Lienhard
MSMohsan Saeed
Mohsan Saeed
MMMargaret R. MacDonald
Margaret R. MacDonald
VCValeria Cagno
Valeria Cagno
Background Tick-borne encephalitis (TBE) virus is the most common tick-transmitted Orthoflavivirus in Europe. Due to its non-specific symptoms, TBE is primarily diagnosed by ELISA-based detection of specific antibodies in the patient serum. However, cross-reactivity between orthoflaviviruses complicates the diagnosis. Specificity problems may be overcome by serum neutralization assays (SNT), however clinically relevant orthoflaviviruses require handling in biosafety level 3 (BSL-3) and they have highly divergent viral kinetics and cell tropisms. Methods We present a reporter viral particle (RVP) based SNT in which the infectivity is measured by luminescence and that can be performed under BSL-2 conditions. Findings The RVP-based SNT for TBEV exhibited a remarkable correlation with the traditional virus-based SNT (R2=0.8614, p<0.0001). Notably, the RVP-based assay demonstrated a sensitivity of 91.7% (95% CI: 87.2-97.1%) and specificity of 100% (95% CI: 79.6-100%). We also tested the cross-reactivity of serum samples in RVP-based assays against other orthoflaviviruses (yellow fever virus, dengue virus type 2, Zika virus, West Nile virus and Japanese encephalitis virus). Interestingly, in 90% of cases where a serum sample had tested TBEV-positive by ELISA but negative by RVP-based SNT, we identified antibodies against other orthoflaviviruses. Interpretations The RVP-based seroneutralization assay show clinical relevance and broad- applicability. Funding This study was supported by Bavarian Nordic grant to R.A. and V.C. Evidence before this study ELISA tests for orthoflavivirus serology are the method of choice in all diagnostic laboratories despite the cross-reactivity issues. Although seroneutralization testing (SNT) provides more reliable results, it requires BSL-3 conditions and approximately a week to obtain the results. However, developing tests with a broader applicability could overcome the problem of cross-reactivity of antibodies against flaviviruses could be overcome leading to a more accurate diagnosis and fewer non-useful results. Although alternative serological tests for other orthoflaviviruses have been investigated they have limitations, including lack of uniformity for different orthoflaviviruses, the need for a BSL-3 laboratory to perform them, and results taking 4-5 days. The reporter viral particle system (RVP) we used in this study has been reported for all orthoflaviviruses, except for YFV. However, its applicability has not been tested in comparison to traditional methods with clinical samples. Added value of this study We tested the RVP system uniformly for different orthoflaviviruses and evaluated the sensitivity and specificity of SNT based on RVP compared to virus-based and to ELISA. Additionally, we found that false positives in ELISA in our clinical samples are frequently related to YFV positive samples. Implications of all the available evidence This study demonstrates the reliability and broad applicability of implementing RVP-based SNT in a clinical setting. This test can overcome the issues of false positive results from ELISA tests. Additionally, our data suggest that it is important to consider YFV exposure or vaccination anamnesis in patient’s medical history. This is consistent with the phylogenetic similarity between YFV and TBEV if compared to other flaviviruses.